On June 30, 2016, Inukai, Takayuki; Takeuchi, Jun; Yasuhiro, Tomoko published a patent.Electric Literature of 869640-41-5 The title of the patent was Preparation of quinoline derivatives for the treatment of Axl-related diseases. And the patent contained the following:
The present invention provides quinoline derivatives I [R1 = (un)substituted alkyl, carbocycle or heterocycle; R2 = (un)substituted alkyl, alkenyl, alkynyl, carbocycle, etc.; R3 = alkyl, halogen, haloalkyl or OR31; R4 = alkoxy, haloalkyl, alkyl, alkenyloxy, etc.; R31 = H, alkyl or haloalkyl; A = CH or N; L = O, NH, C(O), S, etc.; ring 1 = 5- to 7-membered cyclic group; m = 0-3; n = 0-3; q = 0-4] or their salts. For example, 2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxylic acid was subjected to reaction with hydroxylamine hydrochloride followed by coupling with 5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinamine to provide N-[(5E)-5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-5-(hydroxyimino)-2-oxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which underwent Beckmann rearrangement to provide compound II. Compound II exhibited inhibitory activity against Axl with an IC50 value of 0.0015 μM. The invention compounds have strong Axl inhibitory activities and can be useful as therapeutic agents for Axl-related diseases, for example, cancers such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma, kidney diseases, immune system diseases and cardiovascular diseases. The experimental process involved the reaction of 7-Benzyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2(1H)-one(cas: 869640-41-5).Electric Literature of 869640-41-5
The Article related to quinoline derivative preparation axl inhibitor cancer treatment, kidney disease immune system disease cardiovascular disease treatment, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Electric Literature of 869640-41-5
Referemce:
1,8-Naphthyridine – Wikipedia,
1,8-Naphthyridine | C8H6N2 – PubChem